# A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir

> **NCT02323594** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 88 (actual)

## Conditions studied

- Hepatitis C Infection

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Daclatasvir
- **DRUG:** Asunaprevir
- **DRUG:** Daclatasvir

## Key facts

- **NCT ID:** NCT02323594
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2015-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02323594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02323594, "A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02323594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*